Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00378352 · ClinicalTrials.gov registry record · Phase 2
REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction
A Phase 2 study of Acute ST Elevation Myocardial Infarction, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 223
- Enrollment target
- 16
- Study locations
NCT00378352: Completed Phase 2 study of Acute ST Elevation Myocardial Infarction, sponsored by National Institute on Aging (NIA).
NCT00378352 is a Phase 2 study of Acute ST Elevation Myocardial Infarction that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 223 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% higher). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00378352, a Phase 2 study of Acute ST Elevation Myocardial Infarction, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 223 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
Primary Outcome
Infarct size, expressed as percentage of LV mass, assessed by cardiac magnetic resonance (CMR) imaging.
Conditions Studied
Interventions
- DRUG Epoetin alfa
Study Locations (16)
New York
- New York Methodist Hospital - Brooklyn
- Cornell University - New York
- NY Presbyterian Hospital - New York
- Weill Medical College - New York
Michigan
- Henry Ford Hospital - Detroit
- William Beaumont Hospital - Royal Oak
North Carolina
- Duke University - Durham
- Wake Forest University - Winston-Salem
District of Columbia
- Washington Hospital Center - Washington D.C.
Florida
- University of Miami, School of Medicine - Miami
Georgia
- Emory University Hospital - Atlanta
Minnesota
- Mayo Clinic, Rochester - Rochester
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
What the finished NCT00378352 record still lists
NCT00378352 is an interventional study that assigns participants to a tested intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% higher).
The record links to 1 condition, with Acute ST Elevation Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which Epoetin alfa is the first listed.
NCT00378352 lists 16 locations in 11 states (New York, Michigan, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00378352 about?
NCT00378352 is a clinical study titled "REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction". The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
What is the current status of trial NCT00378352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 223 participants. The study started on 2005-09. Estimated completion is 2011-01.
What conditions does trial NCT00378352 study?
This clinical trial studies the following conditions: Acute ST Elevation Myocardial Infarction.
What interventions are being tested in trial NCT00378352?
The interventions under investigation include: Epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00378352?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00378352 being conducted?
This trial has 16 study locations across District of Columbia, Florida, Georgia, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00378352's enrollment target sits among peer trials
223 274th of 2000 higher than 1,727 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06640803 · 223 participants · NA
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
- NCT07175285 · 223 participants
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- NCT07205718 · 223 participants · Phase 1
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia